JPMorgan lowered the firm’s price target on Zai Lab to $64 from $67 and keeps an Overweight rating on the shares following a model update.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ZLAB:
- Cantor biotech/biopharma analysts to hold an analyst/industry conference call
- Zai Lab Obtains Breakthrough Therapy Designation for Efgartigimod Alfa Injection (Subcutaneous Injection) in Patients with Chronic Inflammatory Demyelinating Polyneuropathy in China
- Zai Lab obtains BTD for efgartigimod alfa injection
- Biotech Alert: Searches spiking for these stocks today
- Zai Lab (NASDAQ:ZLAB) Soars 12% on Regulatory Win in China
